# US 2012/0251572 A1 · Hepatitis c virus vaccine composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251572 A1
- Document ID: US20120251572A1
- Status: Published application
- Kind: A1
- Application number: 13/499,009
- Filed: 2010-09-30
- Published: 2012-10-04
- Earliest claimed: 2009-09-30
- Inventors: Takaji Wakita; Masaki Moriyama; Daisuke Akazawa; Noriko Nakamura
- Web page: https://patentgrep.com/patent/US20120251572A1

## CPC

- A61K 39/29: Hepatitis virus
- A61K 39/12: Viral antigens
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2770/24222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24223: Virus like particles [VLP]
- C12N 2770/24234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24263: by chemical treatment
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A combination of an HCV antigen for inducing an antibody having the activity of inhibiting HCV infection and an optimum adjuvant is discovered, so as to provide an effective HCV vaccine composition. The hepatitis C virus vaccine composition comprises: inactivated viral particles obtained by inactivating infectious hepatitis C virus particles prepared from hepatitis C virus genome that contains sequences encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein derived from hepatitis C virus JFH1 strain; an oligonucleotide containing unmethylated CpG, according to SEQ ID NO: 5 in the sequence listing; and aluminium hydroxide.

## Claims

### Claim 1

A hepatitis C virus vaccine composition, comprising:
inactivated viral particles obtained by inactivating infectious hepatitis C virus particles prepared from hepatitis C virus genome that contains sequences encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein derived from hepatitis C virus JFH1 strain;
an oligonucleotide containing unmethylated CpG, according to SEQ ID NO: 5 in the sequence listing; and
aluminium hydroxide.

### Claim 2 (depends on 1)

The hepatitis C virus vaccine composition according to claim 1, wherein the hepatitis C virus genome contains sequences encoding core protein, E1 protein, E2 protein and p7 protein derived from hepatitis C virus J6CF strain.

### Claim 3 (depends on 1, 2)

The hepatitis C virus vaccine composition according to claim 1 or 2, wherein the hepatitis C virus genome contains:
a sequence that encodes 16 amino acid residues from the N-terminal amino acid residue of NS2 protein derived from hepatitis C virus J6CF strain; and
a sequence that encodes a portion ranging from the 17th amino acid residue from the N terminus to the C-terminal amino acid residue of NS2 protein derived from hepatitis C virus JFH1 strain.

### Claim 4

A hepatitis C virus vaccine composition, comprising:
inactivated viral particles obtained by inactivating infectious hepatitis C virus particles containing NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein derived from hepatitis C virus JFH1 strain;
an oligonucleotide containing unmethylated CpG, according to SEQ ID NO: 5 in the sequence listing; and
aluminium hydroxide.

### Claim 5 (depends on 3)

The hepatitis C virus vaccine composition according to claim 3, wherein the infectious hepatitis C virus contains core protein, E1 protein, E2 protein and p7 protein derived from the hepatitis C virus J6CF strain.

### Claim 6 (depends on 4)

The hepatitis C virus vaccine composition according to claim 4, wherein the infectious hepatitis C virus is characterized in that the NS2 protein is a chimeric protein, 16 amino acid residues from the N-terminal amino acid residue of the NS2 protein are derived from the J6CF strain, and a portion ranging from the 17th amino acid residue from the N-terminus to the C-terminal amino acid residue of the NS2 protein is derived from the JFH1 strain.
